[China BD 2024] Allorion and AstraZeneca enters an Option and Global License on EGFR L858R Allosteric Inhibitor Asset

Announced Date: 2024-01-02 (January 2, 2024)

Asset Name: Undisclosed

Licensor (Seller): Allorion Therapeutics (China)

Licensee (Buyer): AstraZeneca

.

Asset Modality: Small Molecule

Asset Target: EGFR L858R Allosteric Inhibitor

Potential Indication: treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC)

Current Stage: Preclinical

.

Scope of Authority:

AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. 

.

Payment Detail:

Allorion is eligible to receive:

Upfront and near-term payments of up to $40 million,

Development and commercial milestone payments of over $500 million.

Tiered royalties on net sales worldwide.

.

Link:

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca (prnewswire.com)

.

Note:

Chinese Name of Allorion Therapeutics, 安锐生物